Compare PTCT & PLXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | PLXS |
|---|---|---|
| Founded | 1998 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.0B |
| IPO Year | 2013 | 1986 |
| Metric | PTCT | PLXS |
|---|---|---|
| Price | $77.48 | $149.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 4 |
| Target Price | $73.76 | ★ $157.50 |
| AVG Volume (30 Days) | ★ 2.3M | 164.5K |
| Earning Date | 11-04-2025 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.11 |
| EPS | ★ 8.94 | 6.26 |
| Revenue | $1,779,150,000.00 | ★ $4,032,966,000.00 |
| Revenue This Year | $128.32 | $10.99 |
| Revenue Next Year | N/A | $7.02 |
| P/E Ratio | ★ $8.64 | $24.02 |
| Revenue Growth | ★ 97.54 | 1.82 |
| 52 Week Low | $35.95 | $103.43 |
| 52 Week High | $87.50 | $172.89 |
| Indicator | PTCT | PLXS |
|---|---|---|
| Relative Strength Index (RSI) | 54.29 | 60.30 |
| Support Level | $73.03 | $141.26 |
| Resistance Level | $79.03 | $151.86 |
| Average True Range (ATR) | 3.38 | 5.09 |
| MACD | -0.70 | 1.22 |
| Stochastic Oscillator | 29.37 | 88.05 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.